BioCentury
ARTICLE | Clinical News

GI-5005: Additional Phase IIb data

November 9, 2009 8:00 AM UTC

Additional data from a prospective subgroup of treatment-naïve patients (n=102) in an open-label Phase IIb trial showed that GI-5005 plus pegylated interferon alpha-2a and ribavirin non-significantly increased response rate vs. pegylated interferon alpha-2a and ribavirin alone at week 48 (70% vs. 55%, p=0.092). Results were similar in treatment-naïve patients in the modified intent-to-treat (mITT) population (n=96), defined as patients having received at least 1 dose of combination therapy (74% vs. 59%, p=0.085). Response was defined as achieving HCV RNA <25 IU/mL. ...